Why factor XI deficiency is a clinical concern

References

• Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953;82:171–174.
   PubMed Web of Science ®Google Scholar
• Rosenthal RL, Dreskin OH, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood. 1955;10:120–131.
   PubMed Web of Science ®Google Scholar
• Wright IS. The nomenclature of blood clotting factors. Canad Med Ass J. 1962;86:373–374.
   PubMed Web of Science ®Google Scholar
• Duga S, Salomon O. Congenital factor XI deficiency: an update. Sem Thromb Hemost. 2013;39:621–631.
   PubMed Web of Science ®Google Scholar
• Santoro C, Di Mauro R, Baldacci E, et al. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia. 2015;21:496–501.
   PubMed Web of Science ®Google Scholar
• James P, Salomon O, Mikovic D, et al. Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia. 2014;20(Suppl 4):71–75.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH. Factor XI deficiency – resolving the enigma? Hematol Am Soc Hematol Educ Program. 2009;97–105. doi:10.1182/asheducation-2009.1.97
   PubMedGoogle Scholar
• Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2014;167:304–326.
   PubMed Web of Science ®Google Scholar
• Gailani D, Neff AT. Rare coagulation factor deficiencies. In: Hoffman R, Nenz EJ, Silberstein LE, et al., editors. Hematology: basic principles and practice. 6th ed. Philadelphia (PA): Saunders-Elsevier; 2010. p. 1939–1952.
   Google Scholar
• Asakai R, Chung DW, Davie EW, et al. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325:153–8.
   PubMed Web of Science ®Google Scholar
• Kadir RA, Economides DL, Lee CA. Factor XI deficiency in women. Am J Hematol. 1999;60:48–54.
   PubMed Web of Science ®Google Scholar
• Berliner S, Horowitz I, Martinowitz U, et al. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coag Fibrinol. 1992;3:465.
   PubMed Web of Science ®Google Scholar
• Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost. 2009;102:487–488.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia. 2006;12:490–3.
   PubMed Web of Science ®Google Scholar
• Ragni MV, Sinha D, Seaman F, et al. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 1985;65:719–724.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Patterson DA, Wensley RT, et al. Definition of the bleeding tendency in factor XI-deficient kindreds: a clinical and laboratory study. Thromb Haemot. 1995;73:194–202.
   PubMed Web of Science ®Google Scholar
• Guéguen P, Galinat H, Blouch MT, et al. Biological determinants of bleeding in patients with heterozygous factor XI deficiency. Br J Haematol. 2012;156:245–251.
   PubMed Web of Science ®Google Scholar
• Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature. 1964;202:498–499.
   PubMed Web of Science ®Google Scholar
• Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science. 1964;145:1310–1312.
   PubMed Web of Science ®Google Scholar
• Luchtman-Jones L, Broze GJ Jr. The current status of coagulation. Ann Med. 1995;27:47–52.
   PubMed Web of Science ®Google Scholar
• Doolittle RF. Step-by-step evolution of vertebrate coagulation. Cold Spring Harb Symp Quant Biol. 2009;74:35–40.
   PubMedGoogle Scholar
• Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost. 2008;6:1876–1883.
   PubMed Web of Science ®Google Scholar
• Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood. 2010;115:2569–2577.
   PubMed Web of Science ®Google Scholar
• Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem. 1991;266:7353–7358.
   PubMed Web of Science ®Google Scholar
• Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science. 1991;253:909–912.
   PubMed Web of Science ®Google Scholar
• Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood. 2011;118:6963–6970.
   PubMed Web of Science ®Google Scholar
• Schmaier AH. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J Thromb Haemost. 2016;14:28–39.
   PubMed Web of Science ®Google Scholar
• Long AT, Kenne E, Jung R, et al. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost. 2016;14:427–437.
   PubMed Web of Science ®Google Scholar
• Bane CE, Ivanov I, Matafonov A, et al. Factor XI deficiency alters the cytokine response and activation of contact proteases during polymicrobial sepsis in mice. Plos 1. 2016;11:e0152968.
   Google Scholar
• Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned? Blood Rev. 2012;26:197–203.
   PubMed Web of Science ®Google Scholar
• Gailani D, Bane CE, Gruber A. Factor XI and contact activation as targets of antithrombotic therapy. J Thromb Haemost. 2015;13:1383–1395.
   PubMed Web of Science ®Google Scholar
• Matafonov A, Sarilla S, Sun MF, et al. Activation of factor XI by products of prothrombin activation. Blood. 2011;118:437–445.
   PubMed Web of Science ®Google Scholar
• Morrissey JH, Smith SA. Polyphophate as a modulator of hemostasis, thrombosis and inflammation. J Thromb Haemost. 2015;13(Suppl 1):S92–97.
   PubMed Web of Science ®Google Scholar
• Geng Y, Verhamme I, Smith SB, et al. The dimeric structure of factor XI and zymogen activation. Blood. 2013;121:3962–3969.
   PubMed Web of Science ®Google Scholar
• Zhou L, Li-Ling J, Huang H, et al. Phylogenetic analysis of vertebrate kininogen genes. Genomics. 2008;91:129–141.
   PubMed Web of Science ®Google Scholar
• Papagrigoriou E, McEwan PA, Walsh PN, et al. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol. 2006;13:557–558.
   PubMed Web of Science ®Google Scholar
• Geng Y, Verhamme IM, Sun MF, et al. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa. J Thromb Haemost. 2013;11:1374–1384.
   PubMed Web of Science ®Google Scholar
• Shpilberg O, Peretz H, Zivelin A, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood. 1995;85:429–432.
   PubMed Web of Science ®Google Scholar
• Peretz H, Mulai A, Usher S, et al. The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood. 1997;90:2654–2659.
   PubMed Web of Science ®Google Scholar
• Meijers J, Mulvihill E, Davie E, et al. Apple 4 in human blood coagulation factor XI mediates dimer formation. Biochemistry. 1992;31:4680–4684.
   PubMed Web of Science ®Google Scholar
• Meijers JC, Davie EW, Chung DW. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood. 1992;79:1435–1440.
   PubMed Web of Science ®Google Scholar
• Zivelin A, Bauduer F, Ducout L, et al. Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood. 2002;99:2448–2454.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Peretz H, Butler R, et al. A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost. 2004;2:918–924.
   PubMed Web of Science ®Google Scholar
• Brenner B, Laor A, Lupo H, et al. Bleeding predictors in factor-XI-deficient patients. Blood Coag Fibrinol. 1997;8:511–515.
   PubMed Web of Science ®Google Scholar
• Kravtsov DV, Wu W, Meijers JC, et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood. 2004;104:128–134.
   PubMed Web of Science ®Google Scholar
• Kravtsov DV, Monahan PE, Gailani D. A classification system for cross-reactive material-negative factor XI deficiency. Blood. 2005;105:4671–4673.
   PubMed Web of Science ®Google Scholar
• Kravtsov DV, Matafonov A, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood. 2009;114:452–458.
   PubMed Web of Science ®Google Scholar
• Livnat T, Shenkman B, Martinowitz U, et al. The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. Thromb Res. 2015;136:465–73.
   PubMed Web of Science ®Google Scholar
• Pike GN, Cumming AM, Hay CR, et al. Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency. Blood. 2015;12:397–405.
   Web of Science ®Google Scholar
• Zucker M, Seligsohn U, Salomon O, et al. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost. 2014;12:1121–1130.
   PubMed Web of Science ®Google Scholar
• Colucci M, Incampo F, Cannavò A, et al. Reduced fibrinolytic resistance in patients with FXI deficiency. Evidence of a thrombin-independent impairment of the TAFI pathway. J Thromb Haemost. 2016. [Epub ahead of print]
   PubMedGoogle Scholar
• Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003;101:4783–4788.
   PubMed Web of Science ®Google Scholar
• Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009;7(Suppl 1):84–87.
   PubMed Web of Science ®Google Scholar
• Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232–40.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Tamarin I, et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis. 2005;16:37–41.
   PubMed Web of Science ®Google Scholar
• Kadir RA, Davies J, Winikoff R, et al. Pregnancy complications and obstetric care in women with inherited bleeding disorders. Haemophilia. 2013;19(Suppl 4):1–10.
   PubMed Web of Science ®Google Scholar
• O’Connell NM, Riddell AF, Pascoe G, et al. Lee CA: recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia. 2008;14:775–781.
   PubMed Web of Science ®Google Scholar
• Riddell A, Abdul-Kadir R, Pollard D, et al. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost. 2011;106:521–527.
   PubMed Web of Science ®Google Scholar
• Setty S, Reddell A, England A, et al. The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency. Haemophilia. 2011;17:906–909.
   PubMed Web of Science ®Google Scholar
• Pike GN, Bolton-Maggs PH. Factor XI-related thrombosis and the role of concentrate treatment in factor XI deficiency. Haemophilia. 2015;21:477–480.
   PubMed Web of Science ®Google Scholar
• Chtourou S, Poulle M. Factor XI. In: Bertoli IJ, Goss N, Curling J, editors. Production of plasma proteins for therapeutic use. New York (NY): John Wiley & Sons; 2012.
   Google Scholar
• Bauduer F, de Raucourt E, Boyer-Neumann C, et al. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study. Haemophilia. 2015;21:481–489.
   PubMed Web of Science ®Google Scholar
• Aledort LM, Goudemand J, Hemoleven Study Group. United States’ factor XI-deficiency patients need a safer treatment. Am J Hematol. 2005;80:301–302.
   PubMed Web of Science ®Google Scholar
• Key NS. Epidemiologic and clinical data-linking factors XI and XII to thrombosis. Hematol Am Soc Hematol Educ Program. 2014;2014:66–70.
   PubMedGoogle Scholar
• Gailani D. Future prospects for contact factors as therapeutic targets. Hematol Am Soc Hematol Educ Program. 2014;2014:52–59.
   PubMedGoogle Scholar